Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study

Pediatric Blood and Cancer

Volumn 55, Issue 4, 2010, Pages 629-638

  George, Rani E ^a   Lahti, Jill M ^b   Adamson, Peter C ^c   Zhu, Kejin ^b   Finkelstein, David ^b   Ingle, A Mark ^d   Reid, Joel M ^e   Krailo, Mark ^d   Neuberg, Donna ^f   Blaney, Susan M ^g   Diller, Lisa ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e Mayo Clinic   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Decitabine; Demethylation; Neuroblastoma; Pediatric solid tumor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 8; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOGLOBIN F; ANTINEOPLASTIC AGENT; AZACITIDINE; DRUG DERIVATIVE; MAGEA1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEVER; GENE EXPRESSION; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE; LEUKOCYTE COUNT; LIVER FUNCTION; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; METHYLATION; MICROARRAY ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; INFANT; MALE; NEOPLASM; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CASPASE 8; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DNA METHYLATION; DOXORUBICIN; FEMALE; FETAL HEMOGLOBIN; GENE EXPRESSION PROFILING; HUMANS; INFANT; MALE; NEOPLASM PROTEINS; NEOPLASMS; NEUROBLASTOMA;

EID: 77957039745     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22607     Document Type: Article

References (50)

1. Fulda S, Kufer MU, Meyer E, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20: 5865-5877.
2. Razin A, Riggs AD. DNA methylation and gene function. Science (New York, NY) 1980; 210: 604-610.
3. Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
4. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005; 74: 481-514.
5. Brown R, Plumb JA. Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther 2004; 4: 501-510.
6. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998; 58: 95-101.
7. DeSimone J, Heller P, Hall L, et al. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982; 79: 4428-4431.
8. Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983; 62: 370-380.
9. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002; 99: 3905-3908.
10. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol 2007; 61: 140-152.
11. Samlowski WE, Leachman SA, Wade M, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23: 3897-3905.
12. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495-5503.
13. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2964.
14. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640.
15. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 2000; 6: 529-535.
16. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J Mol Med (Berlin, Germany) 2001; 79: 428-436.
17. Eggert A, Grotzer MA, Zuzak TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001; 61: 1314-1319.
18. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000; 60: 4315-4319.
19. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 2000; 35: 608-611.
20. Takita J, Yang HW, Chen YY, et al. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 2001; 20: 4424-4432.
21. Astuti D, Agathanggelou A, Honorio S, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001; 20: 7573-7577.
22. Yan P, Muhlethaler A, Bourloud KB, et al. Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Genes Chromosomes Cancer 2003; 36: 129-138.
23. Yang QW, Liu S, Tian Y, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003; 63: 6299-6310.
24. Yang Q, Liu S, Tian Y, et al. Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma. Cancer Res 2004; 64: 4531-4538.
25. van Noesel MM, van Bezouw S, Voute PA, et al. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003; 38: 226-233.
26. Chen B, He L, Savell VH, et al. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res 2000; 60: 3290-3298.
27. Yokochi T, Robertson KD. Doxorubicin inhibits DNMT1, resulting in conditional apoptosis. Mol Pharmacol 2004; 66: 1415-1420.
28. Schwartsmann G, Fernandes MS, Schaan MD, et al. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations. Leukemia 1997; 11: S28-31.
29. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 1993; 7: 49-50.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [see comments]. J Natl Cancer Inst 2000; 92: 205-216.
31. Gu Z, Zhou G. Analytical method development and validation of decitabine in human plasma: XenoBiotic Laboratories, Inc. (XBL); 2002; May 23, 2002.Report. 1-74 pp.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, CA) 2001; 25: 402-408.
33. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.
34. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001; 7: 1698-1705.
35. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-5785.
36. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948-3956.
37. Cashen AF, Shah AK, Todt L, et al. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008; 61: 759-766.
38. Momparler RL, Bouffard DY, Momparler LF, et al. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs 1997; 8: 358-368.
39. van Groeningen CJ, Leyva A, O'Brien AM, et al. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 1277 16) in cancer patients. Cancer Res 1986; 46: 4831-4836.
40. De Smet C, Lurquin C, Lethe B, et al. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 7327-7335.
41. Thibault A, Figg WD, Bergan RC, et al. A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998; 84: 87-89.
42. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol 2003; 51: 231-239.
43. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
44. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899-906.
45. De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996; 93: 7149-7153.
46. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25: 4603-4609.
47. Whitney AR, Diehn M, Popper SJ, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100: 1896-1901.
48. Fan HP, Di Liao C, Fu BY, et al. Interindividual and interethnic variation in genomewide gene expression: Insights into the biological variation of gene expression and clinical implications. Clin Chem 2009; 55: 774-785.
49. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-962.
50. Lemaire M, Chabot GG, Raynal NJ, et al. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 2008; 8: 128.